Hyperthermic intraperitoneal chemotherapy in ovarian cancer: rationale and clinical data

References

• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin.58, 71–96 (2008).
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin.61, 69–90 (2011).
   PubMed Web of Science ®Google Scholar
• McGuire WP III, Markman M. Primary ovarian cancer chemotherapy: current standards of care. Br. J. Cancer89(Suppl. 3), S3–S8 (2003).
   PubMed Web of Science ®Google Scholar
• Dedrick RL, Meyers CE, Bungay PM, DeVita PJ Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat. Rep.62, 1–11 (1978).
   PubMedGoogle Scholar
• Trimble EL, Christian MC. Intraperitoneal chemotherapy for women with advanced epithelial ovarian carcinoma. Gynecol. Oncol.100, 3–4 (2006).
   PubMed Web of Science ®Google Scholar
• Kyrgiou M, Salanti G, Pavlidis N et al. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. J. Natl Cancer Inst.98, 1655–1663 (2006).
   PubMed Web of Science ®Google Scholar
• Elit L, Oliver T, Covens A et al. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer. A systemic review with metaanalysis. Cancer109, 692–702 (2007).
   PubMed Web of Science ®Google Scholar
• de Bree E, Tsiftsis DD. Principles of perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis. Recent Results Cancer Res.169, 39–51 (2007).
   PubMedGoogle Scholar
• Weisberger AS, Levine B, Storaasli JP. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. J. Am. Med. Assoc.159, 1704–1707 (1955).
   PubMed Web of Science ®Google Scholar
• Flessner MF. The transport barrier in intraperitoneal therapy. Am. J. Physiol. Renal Physiol.288, F433–F442 (2005).
   PubMed Web of Science ®Google Scholar
• van der Speeten K, Stuart OA, Sugarbaker PH. Pharmacokinetics and pharmacodynamics of perioperative cancer chemotherapy in peritoneal surface malignancy. Cancer J.15, 216–224 (2009).
   PubMed Web of Science ®Google Scholar
• de Lima Vazquez V, Stuart OA, Mohamed F, Sugarbaker PH. Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics. Cancer Chemother. Pharmacol.52, 108–112 (2003).
   PubMed Web of Science ®Google Scholar
• de Bree E, Witkamp AJ, Zoetmulder FAN. Intraperitoneal chemotherapy for colorectal cancer. J. Surg. Oncol.79, 46–61 (2002).
   PubMed Web of Science ®Google Scholar
• de Bree E, Tsiftsis DD. Experimental and pharmacokinetic studies in intraperitoneal chemotherapy: Ffom laboratory bench to bedside. Recent Results Cancer Res.169, 53–73 (2007).
   PubMedGoogle Scholar
• Sugarbaker PH. Peritonectomy procedures. Surg. Oncol. Clin. N. Am.12, 703–727 (2003).
   PubMedGoogle Scholar
• Ibeanu OA, Bristow RE. Predicting the outcome of cytoreductive surgery for advanced ovarian cancer. A review. Int. J. Gynecol. Cancer20, S1–S11 (2007).
   Google Scholar
• Harter P, Hagmann M, Lieck HJ et al. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann. Surg. Oncol.16, 1324–1330 (2009).
   PubMed Web of Science ®Google Scholar
• Harter P, Sehoul J, Reuss A et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int. J. Gynecol. Cancer21, 289–295 (2011).
   PubMed Web of Science ®Google Scholar
• Eisenkop SM, Spiros NM, Lin WC. ‘Optimal’ cytoreduction for advanced epithelial ovarian cancer: a commentary. Gynecol. Oncol.103, 329–335 (2006).
   PubMed Web of Science ®Google Scholar
• Helm CW. The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. Oncologist14, 683–694 (2009).
   PubMed Web of Science ®Google Scholar
• Vergote I, Trope CG, Amant F et al. Neoadjuvant chemotherapy or primary surgery in stage IIC or IV ovarian cancer. N. Engl. J. Med.363, 943–953 (2010).
   PubMed Web of Science ®Google Scholar
• de Bree E, Romanos J, Michalakis J et al. Intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel as second-line treatment for peritoneal carcinomatosis of gynaecological origin. Anticancer Res.23, 3019–3028 (2003).
   PubMed Web of Science ®Google Scholar
• Garafallo A, Valle M, Garcia J, Sugarbaker PH. Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites. Eur. J. Surg. Oncol.32, 682–685 (2006).
   Google Scholar
• Witkamp AJ, de Bree E, van Goethem AR, Zoetmulder FAN. Rationale and technique of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treat. Rev.27, 365–374 (2001).
   PubMed Web of Science ®Google Scholar
• Hofstra LS, Bos AME, de Vries EGE et al. Kinetic modelling and efficacy of intraperitoneal paclitaxel combined with intravenous cyclophosphamide and carboplatin as first-line treatment in ovarian cancer. Gynecol. Oncol.85, 517–523 (2002).
   Google Scholar
• Markman M, Kulp B, Peterson G et al. Second-line therapy of ovarian cancer with paclitaxel administered by both the intravenous and intraperitoneal routes: Rationale and case reports. Gynecol. Oncol.86, 95–98 (2002).
   Google Scholar
• Rothenberg ML, Liu PY, Braly PS et al. Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: Results from an Intergroup Phase II trial. J. Clin. Oncol.21, 1313–1319 (2003).
   PubMed Web of Science ®Google Scholar
• Kyrgiou M, Salanti G, Pavlidis N et al. Survival benefits with diverse chemotherapy regimens for ovarian cancer: a meta-analysis of multiple treatments. J. Natl Cancer Inst.98, 1655–1663 (2006).
   PubMed Web of Science ®Google Scholar
• Alberts DS, Liu PY, Hannigan EV et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med.335, 150–155 (1996).
   Google Scholar
• Markman M, Bundy B, Alberts DS et al. Phase III study of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol.19, 1001–1007 (2001).
   PubMed Web of Science ®Google Scholar
• de Bree E, Theodoropoulos PA, Rosing H et al. Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: from laboratory bench to bedside. Cancer Treat. Rev.32, 471–482 (2006).
   PubMed Web of Science ®Google Scholar
• de Bree E, Rosing H, Michalakis J et al. Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination. Eur. J. Surg. Oncol.32, 666–670 (2006).
   PubMedGoogle Scholar
• Armstrong DK, Bundy BN, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med.354, 34–43 (2006).
   PubMed Web of Science ®Google Scholar
• Jaaback K, Johnson N. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst. Rev.25, CD005340 (2006).
   Google Scholar
• Helm CW. Ports and complications for intraperitoneal therapy. Br. J. Obstet. Gynecol.119, 150–159 (2012).
   Google Scholar
• Walker JL, Armstrong DK, Huang HQ et al. Intraperitoneal catheter outcomes in a Phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol. Oncol.100, 27–32 (2006).
   PubMed Web of Science ®Google Scholar
• Piccart MJ, Floquet A, Scarfone G et al. Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized Phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int. J. Gynecol. Cancer13(Suppl, 2), 196–203 (2003).
   Google Scholar
• Alberts DS, Hannigan EV, Liu PY et al. Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: an intergroup study. Gynecol. Oncol.100, 133–138 (2006).
   PubMed Web of Science ®Google Scholar
• Fujiwara K, Armstrong D, Morgan M et al. Principles and practice of intraperitoneal chemotherapy for ovarian cancer. Int. J. Gynecol. Cancer17, 1–20 (2007).
   PubMed Web of Science ®Google Scholar
• Takemoto M, Kuroda M, Urano M et al. The effect of various chemotherapeutic agents given at mild hyperthermia on different types of tumours. Int. J. Hyperthermia19, 193–203 (2003).
   PubMed Web of Science ®Google Scholar
• van Ruth S, Verwaal VJ, Hart AA et al. Heat penetration in locally applied hyperthermia in the abdomen during intra-operative hyperthermic intraperitoneal chemotherapy. Anticancer Res.23, 1501–1508 (2003).
   PubMed Web of Science ®Google Scholar
• Markman M. Intraperitoneal taxol. Cancer Treat. Res.81, 1–5 (1996).
   Google Scholar
• Rupniak HY, Whelan RD, Hill BT. Concentration and time-dependent inter-relationships for antitumour drug cytotoxicities against tumour cells in vitro. Int. J. Cancer32, 7–12 (1983).
   PubMed Web of Science ®Google Scholar
• Michalakis J, Georgatos SD, de Bree E et al. Short term exposure of cancer cells to micromolar doses of paclitaxel, with or without hyperthermia, induces long term inhibition of cell proliferation and cell death in vitro. Ann. Surg. Oncol.14, 1220–1228 (2007).
   PubMed Web of Science ®Google Scholar
• Michalakis J, Georgatos SD, Romanos J et al. Micromolar taxol, with or without hyperthermia, induces mitotic catastrophe and cell necrosis in HeLa cells. Cancer Chemother. Pharmacol.56, 615–622 (2005).
   PubMedGoogle Scholar
• Elias DM, Sideris L. Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis. Surg. Oncol. Clin. N. Am.12, 755–769 (2003).
   PubMedGoogle Scholar
• Markman M. Intraperitoneal chemotherapy in the management of malignant disease. Expert Rev. Anticancer. Ther.1, 142–148 (2001).
   PubMedGoogle Scholar
• de Bree E, Rosing H, Filis D et al. Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study. Ann. Surg. Oncol.15, 1183–1192 (2008).
   PubMed Web of Science ®Google Scholar
• Bae JH, Lee JM, Ryu KS et al. Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery. Gynecol. Oncol.106, 193–200 (2007).
   PubMed Web of Science ®Google Scholar
• Piso P, Glockzin G, von Breitenbuch P et al. Patient selection for a curative approach to carcinomatosis. Cancer J.15, 236–242 (2009).
   PubMed Web of Science ®Google Scholar
• Verwaal V, van Ruth S, de Bree E et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J. Clin. Oncol.21, 3737–3743 (2003).
   PubMed Web of Science ®Google Scholar
• de Bree E, Witkamp AJ, Zoetmulder FA. Peroperative hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gastric cancer. Eur. J. Surg. Oncol.26, 630–631 (2000).
   Google Scholar
• Yan TD, Black D, Sugarbaker PH et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann. Surg. Oncol.14, 2701–2713 (2007).
   Google Scholar
• Deraco M, Raspagliesi F, Kusamura S. Management of peritoneal surface component of ovarian cancer. Surg. Oncol. Clin. N. Am.12, 561–583 (2003).
   PubMedGoogle Scholar
• Chi DS, Eisenhauer EL, Zivanovic O et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol. Oncol.114, 26–31 (2009).
   PubMed Web of Science ®Google Scholar
• Bijelic L. Jonson A, Sugarbaker PH. Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer. Ann. Oncol.18, 1943–1950 (2007).
   PubMed Web of Science ®Google Scholar
• Chua TC, Robertson G, Liauw W, Farrell R, Yan TD, Morris DL. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systemic review of current results. J. Cancer Res. Clin. Oncol.135, 1637–1645 (2009).
   PubMed Web of Science ®Google Scholar
• Helm CW, Richard SD, Pan J et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. First report of the HYPER-O Registry. Int. J. Gynecol. Cancer20, 61–69 (2010).
   PubMed Web of Science ®Google Scholar
• Berreder J, Glehen O, Habre J et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from ovarian cancer: a multiinstitutional study of 246 patients. J. Clin. Oncol.27(15S), (2009) (Abstract 5542).
   Google Scholar
• Rufian S, Munoz-Casares FC, Briceno J et al. Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. J. Surg. Oncol.94, 316–324 (2006).
   PubMed Web of Science ®Google Scholar
• Deraco M, Kusamura S, Virzi S et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: a multi-institutional Phase-II trial. Gynecol. Oncol.122, 215–220 (2011).
   PubMed Web of Science ®Google Scholar
• Lim MC, Kang S, Choi J et al. Hyperthermic intraperitoneal chemotherapy after extensive cytoreductive surgery in patients with primary advanced epithelial ovarian cancer: interim analysis of a Phase II study. Ann. Surg. Oncol.16, 993–1000 (2009).
   PubMed Web of Science ®Google Scholar
• Cascales Campos PA, Gil Martinez J, Galindo Fernandez PJ, Gil Gomez E, Martinez Frutos IM, Parrilla Paricio P. Perioperative fast track program in intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery in advanced ovarian cancer. Eur. J. Surg. Oncol.37, 543–548 (2011).
   PubMed Web of Science ®Google Scholar
• Pavlov MJ, Kovacevic PA, Ceranic MS, Stamenkovic AB, Ivanovic AM, Kecmanovic DM. Cytoreductive surgery and modified heated intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer – 12-year single center experience. Eur. J. Surg. Oncol.35, 1186–1191 (2009).
   PubMed Web of Science ®Google Scholar
• Roviello F, Pinto E, Corso G et al. Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary and recurrent ovarian cancer. J. Surg. Oncol.102, 663–670 (2010).
   PubMed Web of Science ®Google Scholar
• Carrabin N, Mithieux F, Meeus P et al. Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer. Bull. Cancer97, E23–E33 (2010).
   PubMedGoogle Scholar
• Rubin SC, Randall TC, Armstrong KA, Chi DS, Hoskins WJ. Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet. Gynecol.93, 21–24 (1999).
   PubMed Web of Science ®Google Scholar
• Gori J, Castano R, Toziano M et al. Intraperitoneal hyperthermic chemotherapy in ovarian cancer. Int. J. Gynecol. Cancer15, 233–239 (2005).
   PubMed Web of Science ®Google Scholar
• Kim JH, Lee JM, Ryu KS et al. Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer. J. Surg. Oncol.101, 149–155 (2010).
   PubMed Web of Science ®Google Scholar
• Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol. Oncol.112, 265–274 (2009).
   PubMed Web of Science ®Google Scholar
• Rasaglieri F, Kusamura S, Campos Torres JC et al. Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: the experience of National Cancer Institute of Milan. Eur. J. Surg. Oncol.32, 671–675 (2006).
   Google Scholar
• Ceelen WP, Van Nieuwebhove Y, Van Belle S, Denys H, Pattyn P. Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer. Ann. Surg. Oncol. doi:10.1245/s10434-009-0878-6 (2009) (Epub ahead of print).
   Google Scholar
• Fagotti A, Costantini B, Vizzielli G et al. HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long-term analysis of outcome. Gynecol. Oncol.122, 221–225 (2011).
   PubMed Web of Science ®Google Scholar
• Munoz-Casares FC, Rufian S, Rubio MJ et al. The role of hyperthermic intraoperative chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer. Clin. Transl. Oncol.11, 753–759 (2009).
   PubMed Web of Science ®Google Scholar
• Ryu KS, Kim JH, Ko HS et al. Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. Gynecol. Oncol.94, 325–332 (2004).
   PubMed Web of Science ®Google Scholar
• de Bree E, Tsiftsis DD, Melissas J. Hyperthermic intraperitoneal chemotherapy (HIPEC) in optimally cytoreduced peritoneal carcinomatosis of gynecology origin: does it provide survival advantage? In: Cytoreductive Surgery in Gynaecologic Oncology: a Multidisciplinary Approach. Yidirim Y (Ed.). Transworld Research Network, Kerala, India, 73–100 (2010).
   Google Scholar
• Helm CW, Bristow RE, Kusamura S et al. Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer. J. Surg. Oncol.98, 283–290 (2008).
   PubMed Web of Science ®Google Scholar
• Katsumata N, Yasuda M, Takahashi F et al. Dose-dense paclitaxel once a week in combination with carboplatin for advanced ovarian cancer: a Phase 3, open-label, randomized controlled trial. Lancet374, 1331–1338 (2009).
   PubMed Web of Science ®Google Scholar
• Kristensen G, Perren T, Qian W et al. Results of interim analysis of overall survival in the GCIG ICON7 Phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. J. Clin. Oncol.29(Suppl.), (2011) (Abstract LBA5006).
   Google Scholar
• Vergote I, Tropé CG, Amant F et al. Neoaduvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N. Engl. J. Med.363, 943–953 (2010).
   PubMed Web of Science ®Google Scholar
• Chua TC, Liauw W, Robertson G, Morris DL. Establishing evidence for change in ovarian cancer surgery – proposing clinical trials of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer peritoneal carcinomatosis. Gynecol. Oncol.115, 166–168 (2009).
   Google Scholar
• Di Giorgio A, Naticchioni E, Biacchi D et al. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer113, 315–325 (2008).
   PubMed Web of Science ®Google Scholar
• Pomel C, Ferron G, Lorimier G et al. Hyperthemic intra-peritoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a Phase II prospective multicentre trial. CHIPOVAC study. Eur. J. Surg. Oncol.36, 589–593 (2010).
   PubMed Web of Science ®Google Scholar
• Frenel JS, Leux C, Pouplin L et al. Oxaliplatin-based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: a pilot study of 31 patients. J. Surg. Oncol.103, 10–16 (2011).
   PubMed Web of Science ®Google Scholar
• Piso P, Dahlke M-H, Loss M, Schlitt HJ. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis. World J. Surg. Oncol.2, 21–28 (2004).
   PubMedGoogle Scholar
• Zanon C, Clara R, Chiappino I et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. World J. Surg.28, 1040–1045 (2004).
   PubMed Web of Science ®Google Scholar
• Helm CW, Randall-Whitis L, Martin RS 3rd et al. Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma. Gynecol. Oncol.105, 90–96 (2007).
   PubMed Web of Science ®Google Scholar
• Cotte E, Glehen O, Mohamed F et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for chemoresistent and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients. World J. Surg.31, 1813–1820 (2007).
   PubMed Web of Science ®Google Scholar
• Königsrainer I, Beckert S, Becker S et al. Cytoreductive surgery and HIPEC in peritoneal recurrent ovarian cancer: experience and lessons learned. Langenbeck Arch. Surg.396, 1077–1081 (2011).
   Google Scholar